Assessing CARsgen Therapeutics Holdings’ Valuation After New CAR T-Cell Manufacturing Cooperation News

Simply Wall St.02-17

CARsgen Therapeutics Holdings (SEHK:2171) has signed cooperation agreements via its subsidiary CARsgen Diagnostics with Shanghai Jingong Enterprise to build a commercial CAR T-cell manufacturing base ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612310744?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-17 10:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612310744","market":"nz","top_or_hot":-1,"title":"Assessing CARsgen Therapeutics Holdings’ Valuation After New CAR T-Cell Manufacturing Cooperation News","media":"Simply Wall St.","content":"<div>\n<p>CARsgen Therapeutics Holdings (SEHK:2171) has signed cooperation agreements via its subsidiary CARsgen Diagnostics with Shanghai Jingong Enterprise to build a commercial CAR T-cell manufacturing base ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/assessing-carsgen-therapeutics-holdings-valuation-after-new\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing CARsgen Therapeutics Holdings’ Valuation After New CAR T-Cell Manufacturing Cooperation News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing CARsgen Therapeutics Holdings’ Valuation After New CAR T-Cell Manufacturing Cooperation News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-17 10:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/assessing-carsgen-therapeutics-holdings-valuation-after-new><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CARsgen Therapeutics Holdings (SEHK:2171) has signed cooperation agreements via its subsidiary CARsgen Diagnostics with Shanghai Jingong Enterprise to build a commercial CAR T-cell manufacturing base ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/assessing-carsgen-therapeutics-holdings-valuation-after-new\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/assessing-carsgen-therapeutics-holdings-valuation-after-new","article_id":"2612310744","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/assessing-carsgen-therapeutics-holdings-valuation-after-new","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612310744","pubTimestamp":1771294682,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CARsgen Therapeutics Holdings (SEHK:2171) has signed cooperation agreements via its subsidiary CARsgen Diagnostics with Shanghai Jingong Enterprise to build a commercial CAR T-cell manufacturing base in Shanghai, a move closely linked to its commercialization plans.\nSee our latest analysis for CARsgen Therapeutics Holdings.\nThe cooperation news comes as momentum in CARsgen Therapeutics Holdings' share price has recently picked up, with a 1-day share price return of 4.65% and a 7-day share...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1587":"次新股","LENZ":"Therapeutics","CAR":"安飞士","BK4139":"生物科技","02171":"科济药业-B","BK1585":"昨日强势股","BK4230":"旅客陆运","BK4007":"制药","BK4539":"次新股","BK4022":"陆运","BK1161":"生物科技"},"translate_title":"新车T细胞制造合作消息后评估科济生物控股的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":0.9,"LENZ":1.5,"CAR":1.5},"content_text":"CARsgen Therapeutics Holdings (SEHK:2171) has signed cooperation agreements via its subsidiary CARsgen Diagnostics with Shanghai Jingong Enterprise to build a commercial CAR T-cell manufacturing base in Shanghai, a move closely linked to its commercialization plans. See our latest analysis for CARsgen Therapeutics Holdings. The cooperation news comes as momentum in CARsgen Therapeutics Holdings' share price has recently picked up, with a 1-day share price return of 4.65% and a 7-day share price return of 8.50%. However, the 90-day share price return of 15.76% contrasts with a stronger 1-year total shareholder return of 33.60%, suggesting that recent enthusiasm is building on a more mixed medium term. If you are watching CAR T-cell names, it could also be worth seeing what else is moving in related areas through our screener of 106 healthcare AI stocks as another set of ideas to research. With CARsgen investing up to RMB 370 million in new capacity and the share price still below the average analyst target, some investors may question whether the stock is undervalued at this level or whether the market is already pricing in future growth. AdvertisementPreferred Price-to-Book of 7.7x: Is it justified? At a last close of HK$15.07, CARsgen Therapeutics Holdings is trading on a P/B of 7.7x, which screens as expensive against both its industry and peer averages. P/B compares the company’s market value to its accounting book value. It is often used for early stage or loss-making biotech businesses where earnings are not yet a stable guide. For CARsgen, this means investors are currently paying a multiple of its net assets that is higher than many other Hong Kong listed biotechs. That premium sits against a mixed backdrop. Earnings are currently in loss, with reduced losses over the past 5 years and forecasts indicating the company is expected to become profitable within 3 years and revenue is forecast to grow faster than the wider Hong Kong market. At the same time, there is insufficient data to run the SWS DCF model on its future cash flows, so there is no cross-check from a cash flow based valuation. The comparison with peers is stark. CARsgen’s 7.7x P/B is higher than the Hong Kong Biotechs industry average of 4.4x and also above the peer average of 5.1x. This suggests the market is assigning a premium price tag relative to similar names. For investors, that raises a clear question: whether the current P/B multiple is paying in advance for future growth that has yet to appear in the financials. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 7.7x (OVERVALUED) However, you still need to weigh risks such as ongoing net losses of CN¥522.057 million and a 3-year total shareholder return decline of 12.59%. Find out about the key risks to this CARsgen Therapeutics Holdings narrative.  Build Your Own CARsgen Therapeutics Holdings Narrative If you see the data differently or prefer to test your own assumptions, you can build a custom view of CARsgen in just a few minutes, starting with Do it your way A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding CARsgen Therapeutics Holdings. Looking for more investment ideas? If you are serious about building a stronger portfolio, do not stop at one stock. Use focused stock lists to spot opportunities others might overlook.  Target potential value opportunities by checking out our list of 222 high quality undervalued stocks that may offer more for every dollar you commit. Protect your capital by reviewing 325 resilient stocks with low risk scores that score well on our risk checks before you put more money to work. Get ahead of the crowd by scanning our screener containing 572 high quality undiscovered gems that combine quality fundamentals with lower market attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612310744","isCrawlerRequest":true}